Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.

Cancer medicine - 1 Jan 2025

Li Xiao-Lan, Zhou Jianbiao, Tang Nicole Xin-Ning, Chai Yi, Zhou Meng, Gao Ai-di, Lu Zhong-Kai, Min Han

Abstract excerpt

BACKGROUND: The toxicity and drug resistance associated with oxaliplatin (L-OHP) limit its long-term use for colorectal cancer (CRC) patients. p53 mutation is a common genetic trait of CRC. PRIMA-1met (APR-246, eprenetapopt) restores the DNA-binding capacity of different mutant P53 proteins. PRIMA-1met has progressed to the Phase III clinical trial. Our study explores the combination therapy of PRIMA-1met and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colorectal Neoplasms

Share to Drug Synergism

Share to HCT116 Cells

Share to Mice, Nude

Share to Oxaliplatin

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 39757707
DOI: 10.1002/cam4.70530
PMCID: PMC11702439

Genes

CCK
DLD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Mechanisms of Synergistic Effect of PRIMA-1met and Oxaliplatin in Colorectal Cancer With Different p53 Status.PMID 39757707Read ↗

PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanismsSemantic proximity Read ↗

Network Modeling of MDM2 Inhibitor-Oxaliplatin Combination Reveals Biological Synergy in wt-p53 solid tumorsSemantic proximity Read ↗

P53 reactivator PRIMA-1 MET synergizes with 5-Fluorouracil to induce apoptosis in pancreatic tumor cellsSemantic proximity Read ↗

Synergistic Antitumor Activity of SUMO1 degrader and Oxaliplatin through G6PD Inhibition in Colorectal CancerSemantic proximity Read ↗

Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolutionSemantic proximity Read ↗

Oxaliplatin induces different cellular and molecular chemoresistance patterns in colorectal cancer cell lines of identical origins.Semantic proximity Read ↗

AI-Enhanced RAIN Protocol: A Systematic Approach to Optimize Drug Combinations for Rectal Neoplasm TreatmentSemantic proximity Read ↗

Identification of a six-gene signature predicting overall survival for Oxaliplatin and 5-Fluorouracil resistant Colon cancer and potential drug-repurposingSemantic proximity Read ↗

Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database.Semantic proximity Read ↗

FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer CellsSemantic proximity Read ↗

PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis.Semantic proximity Read ↗

CDK4/6 inhibitors enhance oxaliplatin efficacy in colorectal cancer with RB-dependent and tumor-selective activity in intestinal modelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.